Parthenon Therapeutics Announces Publication in Journal for ImmunoTherapy of Cancer on the Role of Immune Exclusion in Cancer

Precision oncology company Parthenon Therapeutics has had an article published in the Journal for ImmunoTherapy of Cancer (JITC) that identified key characteristics and issues relevant to the role immune exclusion plays in resistance to checkpoint therapy. The work was performed in collaboration with multiple US and international academic institutions. Parthenon recently initiated a Phase 1 tria..